User profiles for Erique Lukong

Kiven Erique Lukong

University of Saskatchewan
Verified email at usask.ca
Cited by 3255

[HTML][HTML] Mesenchymal stromal cells' role in tumor microenvironment: involvement of signaling pathways

…, PFS Etet, JM Muller, G Bassi, E Lukong… - Cancer biology & …, 2017 - ncbi.nlm.nih.gov
Mesenchymal stromal cells (MSCs) are adult multipotent stem cells residing as pericytes in
various tissues and organs where they can differentiate into specialized cells to replace …

Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog

…, PF Seke Etet, JM Muller, G Bassi, E Lukong… - Cancer Biology & …, 2017 - iris.univr.it
Master developmental pathways, such as Notch, Wnt, and Hedgehog, are signaling systems
that control proliferation, cell death, motility, migration, and stemness. These systems are …

[HTML][HTML] Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog

…, PFS Etet, JM Muller, G Bassi, E Lukong… - Cancer Biology & …, 2017 - ncbi.nlm.nih.gov
Master developmental pathways, such as Notch, Wnt, and Hedgehog, are signaling systems
that control proliferation, cell death, motility, migration, and stemness. These systems are …

[HTML][HTML] Understanding breast cancer–The long and winding road

KE Lukong - BBA clinical, 2017 - Elsevier
Background Despite a remarkable increase in the depth of our understanding and management
of breast cancer in the past 50 years, the disease is still a major public health problem …

[HTML][HTML] Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression

KE Lukong, D Larocque, AL Tyner, S Richard - Journal of Biological …, 2005 - ASBMB
The breast tumor kinase (BRK) is a growth promoting non-receptor tyrosine kinase
overexpressed in the majority of human breast tumors. BRK is known to potentiate the epidermal …

[HTML][HTML] Breast cancer stem-like cells in drug resistance: a review of mechanisms and novel therapeutic strategies to overcome drug resistance

T Saha, KE Lukong - Frontiers in oncology, 2022 - frontiersin.org
Breast cancer is the most frequent type of malignancy in women worldwide, and drug resistance
to the available systemic therapies remains a major challenge. At the molecular level, …

Signaling pathways in breast cancer: therapeutic targeting of the microenvironment

…, L Vecchio, JM Muller, M Krampera, KE Lukong - Cellular signalling, 2014 - Elsevier
Breast cancer is the most common cancer in women worldwide. Understanding the biology
of this malignant disease is a prerequisite for selecting an appropriate treatment. Cell cycle …

Breast cancer in Africa: prevalence, treatment options, herbal medicines, and socioeconomic determinants

KE Lukong, Y Ogunbolude, JP Kamdem - Breast cancer research and …, 2017 - Springer
Breast cancer is the leading cause of cancer-related deaths in women worldwide. GLOBOCAN
estimated about 1.7 million new cases of breast cancer diagnoses worldwide and about …

[HTML][HTML] Triple negative breast cancer: Approved treatment options and their mechanisms of action

A Mandapati, KE Lukong - Journal of cancer research and clinical …, 2023 - Springer
Purpose Breast cancer, the most prevalent cancer worldwide, consists of 4 main subtypes,
namely, Luminal A, Luminal B, HER2-positive, and Triple-negative breast cancer (TNBC). …

Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology

RK Goel, KE Lukong - Cancer and Metastasis Reviews, 2016 - Springer
The non-receptor tyrosine kinase Fyn-related kinase (FRK) is a member of the BRK family
kinases (BFKs) and is distantly related to the Src family kinases (SFKs). FRK was first …